Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.90 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239889 | 1.00 | CHRNA7 (0.90) | CHRNA7TAAR1TSHROPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL7516224 | 0.98 | CHRNA7 (0.87) | CHRNA7TAAR1TSHROPRM1OPRK1 | |
| SCHEMBL2811534 | 0.95 | CHRNA7 (1.00) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL7509300 | 0.93 | CHRNA7 (0.96) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| Iodide SCHEMBL7016592 | 0.93 | CHRNA7 (0.96) | CHRNA7TAAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL5899579 | 0.91 | CHRNA7 (0.80) | CHRNA7TAAR1TSHROPRM1OPRK1 | |
| SCHEMBL20137193 | 0.91 | CHRNA7 (0.80) | CHRNA7TAAR1TSHROPRM1OPRK1 | |
| SCHEMBL9737757 | 0.89 | CHRNA7 (0.77) | CHRNA7TAAR1TSHROPRM1OPRK1 | |
| SCHEMBL5264779 | 0.89 | CHRNA7 (0.77) | CHRNA7TAAR1TSHROPRM1OPRK1 | |
| SCHEMBL10753534 | 0.89 | CHRNA7 (0.82) | CHRNA7TAAR1OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0047105-A1 | Benzoquinolizines, processes for their preparation and pharmaceutical compositions | JOHN WYETH & BROTHER LIMITED (GB) | 1982-03-10 | — | — | EP | claimed |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | GEORGETOWN UNIVERSITY (US) | 2026-03-26 | — | — | US | disclosed |
| US-20200352917-A1 | MEDICATED SPRAY FOR TREATMENT OF SUBSTANCE ABUSE, OVERDOSE, ADDICTION AND IMPULSE CONTROL DISORDERS | GOOBERMAN LANCE L (US) | 2020-11-12 | — | — | US | disclosed |
| US-20180273533-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2018-09-27 | — | — | US | disclosed |
| US-9988382-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-8562949-B2 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-10-22 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| US-20080050312-A1 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070098781-A1 | Modified release compositions for DPP-IV inhibitors | HOFFMANN-LA ROCHE INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273533-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | SLC18A2, SLC6A2, SLC18A1 | CHRNA7 584/4885TAAR1 476/4885TSHR 1602/4885 |
| US-20070098781-A1 | Modified release compositions for DPP-IV inhibitors | DPP4, DPP3, DPP7 | CHRNA7 3351/4885TAAR1 3496/4885TSHR 2397/4885 |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | SLC18A2, SLC6A2, SLC18A1 | CHRNA7 584/4885TAAR1 476/4885TSHR 1602/4885 |
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | PAX3, FOXO1, PAXBP1 | CHRNA7 2245/4885TAAR1 4749/4885TSHR 2791/4885 |
| US-20080050312-A1 | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | SLC18A2, SLC18A3, SLC6A2 | CHRNA7 301/4885TAAR1 133/4885TSHR 1184/4885 |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | UGT2B7, CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRNA7 311/4885TAAR1 3574/4885TSHR 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.